Hype, translated
into standards.
Regenerative medicine has a vocabulary problem. Marketing phrases carry more weight than the evidence supports. Here's how to translate each one back into plain, defensible language.
Serious medicine speaks in numbers, names, and documents, not adjectives.
"Miraculous," "revolutionary," "breakthrough" are tells, not descriptors.
If it can't be said plainly, it probably shouldn't be said.
What they
say · what it means.
"Miraculous recovery"
Plain · A subset of patients experience meaningful improvement. A subset don't. Serious clinics cite the distribution, not the highlight reel.
"95% success rate"
Plain · No honest number exists at that level in regenerative medicine. The response rate in well-screened candidates typically lands 50–75%, depending on indication.
"Cutting-edge proprietary protocol"
Plain · We don't publish what we do. Proprietary is not a medical standard, it's a marketing shield. Ask what the cell type, dose, and route are. Ask what the follow-up schedule is.
"FDA-compliant facility"
Plain · This usually means the lab or clinic operates in a framework with FDA guidance somewhere in its background. It does not mean the therapy is FDA-approved. Those are very different statements.
"Stem cells can treat anything"
Plain · They can't. Specific cell types have rationale in specific indications. Broad claims are the clearest signal that a clinic is outside the evidence.
"Regrow your cartilage"
Plain · Current MSC therapy does not reliably regrow lost cartilage. It can modulate the joint environment, reduce inflammatory burden, and slow progression in well-screened candidates. "Regrow" is a claim the biology doesn't consistently support.
"Permanent results"
Plain · Durability for IV MSC therapy is measured in months to low years. Joint response can last longer but is not permanent. Anyone saying "permanent" is selling, not informing.
"No risks"
Plain · Every biologic therapy has risk profiles. Most are low with proper screening, but "no risks" is a phrase that disqualifies the speaker.
Plainer
language.
"We accept this indication. We decline these."
Clinics that say yes to everything are not clinics that say yes carefully.
"The response rate we see is X in well-screened Y candidates."
Specific. Indication-bounded. Acknowledges that screening matters.
"Here's what happens if you don't respond."
Non-response is real. Clinics that plan for it are more honest than clinics that deny it.
"Here are the published studies. Here are their limitations."
Citations with caveats. Not "studies show."
"Here's the named lab. Here's the release document."
Traceable sourcing. No shield of proprietary.
"Here's the price, itemized."
Pricing is a medical standards question too. Withheld price is rarely a patient-friendly choice.
We wrote
this on ourselves.
Read our site with this translator on. If you find us saying "miraculous" or "95%" or "no risks," call it out. We'd rather be corrected than be inconsistent.
Better: take the checklist to any other clinic you're evaluating. The translation works on everyone.
Plain language isn't modesty, it's just what's defensible. Anything stronger than "a meaningful subset of well-screened candidates experience measurable response" has to come with citations, and most of the time those citations don't exist.
Standards
questions.
Q.01Isn't some marketing just normal business?
Q.02Are there times stem cell therapy really is dramatic?
Keep
reading.
Plainer
language.
Carry the translator into your next consult. Ask why each adjective is there.